In a randomized, single-blind, 24-week study, participants assigned to dual therapy of 2 mg weekly of the GLP-1 receptor agonist exenatide (Bydureon, AstraZeneca) and 10 mg daily of the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) lost more weight than those taking either agent alone or those receiving dapagliflozin and metformin extended-release (Xigduo XL, AstraZeneca) or phentermine/topiramate extended-release (Qsymia, Vivus)
Sticking to a steady weekly dosing schedule is good for getting the best results
These are two fundamentally different mechanisms targeting different points in the inflammatory cascade
What role does semaglutide GLP-1 play in controlling blood sugar and weight
A total of 1,133 participants had all four SUD diagnoses (0.8%)
The peptide is stuck, progress is slow, and there's a higher chance of problems along the way